Following the renewal, Canaan sold a total of 4.8 million American depositary shares through the ATM program at a combined average price of $1.61 per ADS, resulting in total proceeds of $7.8 million.

NiSource Inc. (NYSE: NI) ("NiSource", "we" and "our") announced today that it has established an "at-the-market" equity offering program under which NiSource may sell shares of its common stock, par ...

On October 29, 2025, Predictive Oncology Inc. filed a prospectus supplement to update its at-the-market (ATM) offering program, allowing the sale of up to $18,330,000 in common stock. This move aims ...

Châtillon, France, October 29, 2025DBV Technologies Announces Sale of approximately $30 million of ADSs Through its ...

Approximately US$7.8 million raised at an average price of approximately US$1.61 per ADS Company to pause further ATM Sales through 2025 SINGAPORE, Oct. 31, 2025 /PRNewswire/ -- Canaan Inc. (NASDAQ: ...

Strategy MSTR reported third-quarter 2025 earnings of $8.42 per share against the year-ago quarter loss of $1.56 per share.

Investing.com -- Canaan Inc (NASDAQ:CAN) stock surged 10.1% on Friday after the crypto mining company announced it has ceased further sales under its at-the-market (ATM) equity offering program for ...

The volume and timing of distributions under the ATM Program, if any, will be determined in the Trust's sole discretion. The Trust intends to use the proceeds from the ATM Program, if any, to acquire ...

Discover key insights from Invesco Mortgage Capital’s Q3 2025 earnings: agency RMBS gains, capital strategies, and outlook for investors.

NWTG READ THE FULL NWTG RESEARCH REPORT At-The-Market Equity Offering On October 24, 2025, Newton Golf (NASDAQ:NWTG) initiated an ATM equity offering for up to $10.0 million. Under the ATM program, ...

Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV - ISIN: ...

Daix (France), New York City (New York, United States), October 14, 2025 - Inventiva (Euronext Paris and Nasdaq : IVA) ("Inventiva” or the "Company”), a clinical-stage biopharmaceutical company ...